Global Central Nervous System Biomarkers Market Size (2024 - 2029)

Central Nervous System Biomarkers Market Analysis

The Global Central Nervous System Biomarkers Market size is estimated at USD 5.61 billion in 2024, and is expected to reach USD 8.12 billion by 2029, growing at a CAGR of 7.67% during the forecast period (2024-2029).

COVID-19 cases worldwide had a profound impact on the CNS biomarkers market. Based on the study "Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity," published in January 2021, various studies found frequent reporting of neurological symptoms in patients hospitalized due to COVID-19. Thus, the researchers examined cerebrospinal fluid (CSF) from patients with neurological manifestations of COVID-19 for biomarkers of the central nervous system (CNS) injury and other pathology in relation to neurological symptoms and disease severity. Therefore, future studies in larger samples are needed to explore and understand the genesis of neurological injury in COVID-19 patients.

A biomarker is used to measure the biological state, presence of diseases, and effects of treatments. The advancements in the fields of genomics and proteomics during the past decade have improved awareness regarding genetic regulatory pathways related to (central nervous system) CNS biomarkers. The proteomics technologies have advanced in various areas of drug discovery and development through a comparative assessment of normal and diseased tissues. Proteomics research has great potential in the discovery of relevant protein biomarkers in both diagnostics and therapies for the central nervous system. It plays a crucial role in earlier disease diagnosis, prognosis, and monitoring of the development of central nervous disease.

There is also an increasing number of pipeline studies for the development of biomarkers in various disease conditions, which is expected to boost the central nervous system biomarkers market growth. According to the study "Biomarkers in tumors of the central nervous system" published in 2019, specific diagnostic, prognostic, and predictive biomarkers were detected, and they continue to emerge. Hence, the knowledge of specific biomarkers is of great importance for individualized treatment and follow-up.

Therefore, advanced imaging systems are aiding the early diagnosis of various diseases while reducing the mortality rate. The development in related technologies, such as genomics, proteomics, and imaging system, is reflected in the evolution of newer biomarkers. Considering the complexity of the central nervous system (CNS), biomarkers are now expected to play a significant role in the identification of several neurodegenerative diseases at an early stage, provide enhanced diagnosis, and eventually better treatment.

However, the high cost of CNS biomarker testing and diagnostics and certain issues related to regulatory and reimbursement systems are found to be the hindering factors impacting the growth of the market.

Central Nervous System Biomarkers Industry Segmentation

As per the scope of the report, central nervous system (CNS) biomarkers are used clinically to screen for, diagnose, or monitor the activity of CNS-related diseases to guide molecularly targeted therapy or assess therapeutic response. Biomarkers help understand the development of chronic diseases and their relationship with environmental chemicals and identify subjects who are at high risk of developing diseases. The central nervous system biomarkers market is segmented by type of CNS biomarkers (safety biomarker, efficacy biomarker, validation biomarker, and other types of CNS biomarkers), application (drug discovery and development, personalized medicine, and other applications), end user (diagnostic labs, clinics/hospitals, and research centers), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.